Single-center, Prospective Study on the Identification and Delineation of Brain and Lung Tumors and At-Risk Organs, and Functional Testing of Surrounding Tissues Based on Dual-Energy CT

Tianjin Medical University Cancer Institute and Hospital1 site in 1 country50 target enrollmentApril 28, 2023

ConditionsImage Quality and Contouring Accuracy of the Tumor in Radiotherapy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Image Quality and Contouring Accuracy of the Tumor in Radiotherapy
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Enrollment: 50
Locations: 1
Primary Endpoint: DICE value
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study explored the feasibility of dual-energy CT in head and lung tumors. Dual-energy CT can achieve quantitative CT imaging based on traditional imaging by dual-energy spectral imaging, and enhance the clarity of head and lung tumors. In this study, we will prospectively explore the image accuracy and delineation accuracy of dual energy CT in radiotherapy to verify whether dual energy CT performs better with conventional CT.

Registry

clinicaltrials.gov

Start Date

April 28, 2023

End Date

December 31, 2024

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Voluntarily participate in and sign the informed consent in person.
•Over 18 years old, gender unlimited;
•After imaging diagnosis of primary lung cancer or space-occupying lung lesions with oligometastases, MDT decided to treat SBRT
•Clinical stage IA-IV (cT1-4N1-3M0-1);
•No serious abnormality of blood system, heart, lung, liver, kidney function and immune deficiency;
•Coagulation function: activated partial thromboplastin time (APTT) \< the upper limit of normal 10 seconds, prothrombin time (PT) \< the upper limit of normal 3 seconds, plasma fibrinogen 2-4g/L;
•Hemoglobin ≥100g/L, WBC≥4×109/L, neutrophils ≥1.5×109/L, platelets ≥100×109/L
•Bilirubin \< 1.5 times the upper limit of normal value; Glutamic oxalic aminotransferase (ALT) \& Glutamic pyruvic aminotransferase (AST) ≤1.5 times the upper limit of normal value;
•Serum creatinine ≤1.5 times the upper limit of normal value;
•The willingness of men or women of childbearing age to use contraception in the trial;

Exclusion Criteria

•Patients could not tolerate or were unwilling to undergo CT examination;
•The primary lesion has undergone surgery or radiotherapy or chemotherapy or targeted or immunotherapy;
•Subjects who have received other drug trials within the last 1 month;
•People with severe allergic history or idiosyncrasies;
•Patients with a history of severe lung or heart disease;
•Severe comorbidities, such as uncontrolled hypertension, heart failure, etc.;
•Pregnant or lactating women;
•Previous history of malignant tumor;
•Refusal or inability to sign informed consent to participate in the trial;
•Currently or planning to participate in other clinical trials; 11,Can not acquire MRI scanning